Overview
Founded in 1916 and headquartered in Melbourne, Australia, CSL Limited is widely considered the leader in Australian healthcare and one of the largest global biotechnology companies specializing in plasma-derived therapies, vaccines, and treatments.
CSL operates through CSL Behring, CSL Seqirus, and CSL Vifor segments, focusing on 3 different fields, including plasma-derived therapies, vaccines and iron deficiency & nephrology therapies. As the core business of CSL, which contributes ~70-80% of revenue, CSL Behring's model is integrated vertically by collecting plasma through a global donation network and converting it into high-value biologic therapies in order to maintain a durable competitive advantage.
Growth potential
By taking advantage of the growth of demand for plasma-derived medicines and one of the largest plasma collection networks with decades of manufacturing expertise, CSL shows an opportunity to sustain a leading position in an industry with stable long-term growth potential. In fact, unlike cyclical businesses, healthcare has been one of the best performing sectors during the financial crises.
With the position as defensive assets, healthcare stocks, led by CSL, can expect capital to potentially rotate back after the market excitement on technology and finance, especially in this period of geopolitical instability. Price Valuation Following a significant decline from its peak valuation, CSL’s share is now traded at a significantly lower price than analysts’ estimates of fair value. With a dividend yield of around 2.3%, compared to its 5-year average of 1.50%, CSL now is also trading above its historical average dividend yield. This discount offers a more attractive entry point for long-term investors who believe in the durability of the biotech sector
Recent Issues
However, this pullback has also signaled underlying concerns around CSL’s recent earnings performance and operational headwinds.
Earnings growth has declined sharply, especially in FY25, with only US$1,396 compared with over US$2,000 throughout the 2019-2024 period. This is partly because of the higher plasma collection costs and post-pandemic operational adjustments. These financial pressures have resulted in the failure to meet investors’ expectations as well as weighed on investor sentiment in the short term.
Long-term thesis
Despite these short-term challenges, CSL continues to invest heavily in expanding plasma collection capacity and improving operational efficiency. This allows investors to have expectations about CSL's position and its recovery over the long term as global healthcare demand and plasma supply normalise.
Risks and conclusion
While regulatory risks, cost pressures, and competitive biotech innovation remain key uncertainties, CSL's preeminent position in plasma therapeutics and the growth potential of the healthcare industry still make it an intriguing long-term stock for investors.
Have other thoughts on CSL?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user VinhVu holds no position in ASX:CSL. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
